MCID: SML001
MIFTS: 60

Small Cell Carcinoma

Categories: Cancer diseases, Genetic diseases, Rare diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Small Cell Carcinoma

MalaCards integrated aliases for Small Cell Carcinoma:

Name: Small Cell Carcinoma 12 15 17
Small Cell Carcinoma, Intermediate Cell 12 74
Small Cell Carcinoma - Intermediate Cell 12
Intermediate Cell Small Cell Carcinoma 12
Small Cell Carcinoma of Lung 74
Carcinoma, Small Cell 74

Classifications:



External Ids:

Disease Ontology 12 DOID:0050685
NCIt 51 C4099
SNOMED-CT 69 5958006

Summaries for Small Cell Carcinoma

Disease Ontology : 12 A carcinoma that is an undifferentiated neoplasm composed of primitive-appearing cells.

MalaCards based summary : Small Cell Carcinoma, also known as small cell carcinoma, intermediate cell, is related to lung combined type small cell carcinoma and ureter small cell carcinoma. An important gene associated with Small Cell Carcinoma is ENO2 (Enolase 2), and among its related pathways/superpathways are Endometrial cancer and Downstream signaling events of B Cell Receptor (BCR). The drugs Etoposide and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include prostate, lung and brain, and related phenotypes are Decreased viability in esophageal squamous lineage and cellular

Related Diseases for Small Cell Carcinoma

Diseases in the Small Cell Carcinoma family:

Basal Cell Carcinoma 1 Basal Cell Carcinoma 2
Basal Cell Carcinoma 3 Basal Cell Carcinoma 4
Basal Cell Carcinoma 5 Basal Cell Carcinoma 6
Basal Cell Carcinoma 7 Cell Type Cancer
Basal Cell Carcinoma Large Cell Carcinoma
Basal Cell Carcinoma, Multiple

Diseases related to Small Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 522)
# Related Disease Score Top Affiliating Genes
1 lung combined type small cell carcinoma 34.5 NCAM1 SYP
2 ureter small cell carcinoma 34.4 CHGA SYP
3 gastric small cell carcinoma 33.7 CHGA ENO2 NCAM1 PTPRC SYP
4 gallbladder small cell carcinoma 33.7 CHGA ENO2 KRT7 NCAM1 SYP
5 small cell carcinoma of the bladder 33.6 CHGA ENO2 KRT20 KRT7 NKX2-1 SYP
6 prostate small cell carcinoma 33.5 ENO2 KIT KLK3 NKX2-1 PTEN
7 endometrial small cell carcinoma 33.4 ENO2 KIT NCAM1 PDGFRA PTPRC SYP
8 cervix small cell carcinoma 33.3 CDKN2A CHGA ENO2 NCAM1 SYP TP53
9 penile cancer 31.4 CDKN2A EGFR TP53
10 merkel cell carcinoma 31.1 CHGA ENO2 KIT KRT20 KRT7 NCAM1
11 small cell cancer of the lung 30.9 CALCA CDKN2A CHGA EGFR ENO2 KIT
12 adenocarcinoma 30.5 CDKN2A EGFR KIT PTEN TP53
13 pulmonary large cell neuroendocrine carcinoma 30.5 CHGA ENO2 SYP
14 lung cancer 30.4 CDKN2A CHGA EGFR ENO2 KIT KRT20
15 carcinoid syndrome 30.4 CALCA CHGA ENO2 SYP
16 rhabdoid cancer 30.3 ENO2 SMARCA4 SYP TP53
17 ovarian mucinous neoplasm 30.2 KRT20 KRT7 SYP
18 in situ carcinoma 30.1 CDKN2A EGFR TP53
19 achalasia 30.0 ENO2 KIT TP53
20 tubular adenocarcinoma 30.0 CHGA KRT20 SYP
21 paraganglioma 30.0 CHGA ENO2 SYP
22 linitis plastica 30.0 KRT20 KRT7
23 follicular adenoma 29.9 CALCA NKX2-1 PTEN
24 lung oat cell carcinoma 29.9 CALCA CHGA ENO2
25 atypical teratoid rhabdoid tumor 29.9 SMARCA4 SYP TP53
26 mucinous cystadenocarcinoma 29.9 KRT20 KRT7 PTPRC
27 barrett esophagus 29.8 CDKN2A KRT20 KRT7 TP53
28 teratoma 29.7 ENO2 KIT KRT7 NKX2-1 SYP TP53
29 dermoid cyst 29.7 CHGA KIT KRT20 KRT7
30 pleomorphic carcinoma 29.6 EGFR KRT7 NKX2-1 TP53
31 rhabdomyosarcoma 29.6 ENO2 PDGFRA PTPRC TP53
32 cystic teratoma 29.6 ENO2 KRT20 KRT7 NKX2-1 SYP TP53
33 mesothelioma, malignant 29.5 CDKN2A KRT20 KRT7 NKX2-1
34 adenosquamous carcinoma 29.5 EGFR KIT KRT7 NKX2-1 TP53
35 large cell carcinoma 29.5 CHGA EGFR ENO2 KRT7 NCAM1 NKX2-1
36 large cell neuroendocrine carcinoma 29.5 CHGA EGFR ENO2 KIT KRT20 KRT7
37 mammary paget's disease 29.5 CALCA EGFR KRT20 KRT7
38 pheochromocytoma 29.5 CALCA CHGA ENO2 NCAM1 SYP
39 endocervical adenocarcinoma 29.4 CDKN2A KRT20 KRT7 TP53
40 cervical adenocarcinoma 29.4 CDKN2A KRT20 KRT7 TP53
41 pulmonary blastoma 29.4 CHGA EGFR NKX2-1 SYP TP53
42 suppression of tumorigenicity 12 29.4 CHGA KLK3 PTEN TP53
43 basaloid squamous cell carcinoma 29.4 CDKN2A EGFR ENO2 KRT7 SYP TP53
44 breast adenocarcinoma 29.4 CALCA EGFR PTEN TP53
45 meningioma, familial 29.4 CDKN2A ENO2 PTEN SYP TP53
46 li-fraumeni syndrome 29.4 CDKN2A EGFR PTEN TP53
47 renal cell carcinoma, nonpapillary 29.3 EGFR KIT KRT20 KRT7 NKX2-1
48 lung cancer susceptibility 3 29.3 CDKN2A EGFR KRT20 KRT7 NKX2-1 TP53
49 vulva cancer 29.3 CDKN2A EGFR KRT7 TP53
50 adenoid cystic carcinoma 29.2 KIT KRT20 KRT7 PTEN SMARCA2 TP53

Graphical network of the top 20 diseases related to Small Cell Carcinoma:



Diseases related to Small Cell Carcinoma

Symptoms & Phenotypes for Small Cell Carcinoma

GenomeRNAi Phenotypes related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.32 CDKN2A CHGA KIT KLK3 KRT7 NKX2-1

MGI Mouse Phenotypes related to Small Cell Carcinoma:

47 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.39 CDKN2A EGFR ENO2 KIT KRT7 NCAM1
2 growth/size/body region MP:0005378 10.33 CDKN2A CHGA EGFR ENO2 KIT NKX2-1
3 homeostasis/metabolism MP:0005376 10.31 CDKN2A CHGA EGFR KIT KRT7 NKX2-1
4 endocrine/exocrine gland MP:0005379 10.3 CDKN2A CHGA EGFR KIT NKX2-1 PDGFRA
5 digestive/alimentary MP:0005381 10.27 CDKN2A EGFR KIT NKX2-1 PDGFRA PTEN
6 mortality/aging MP:0010768 10.27 CDKN2A CHGA EGFR KIT NCAM1 NKX2-1
7 nervous system MP:0003631 10.25 CDKN2A CHGA EGFR ENO2 KIT NCAM1
8 cardiovascular system MP:0005385 10.24 CDKN2A CHGA EGFR KIT NKX2-1 PDGFRA
9 neoplasm MP:0002006 10.16 CDKN2A EGFR KIT NKX2-1 PDGFRA PTEN
10 integument MP:0010771 10.13 CDKN2A EGFR KIT PDGFRA PTEN SMARCA2
11 muscle MP:0005369 10.13 CDKN2A CHGA EGFR KIT PDGFRA PTEN
12 liver/biliary system MP:0005370 10.05 CDKN2A EGFR KIT PTEN PTPRC SMARCA4
13 normal MP:0002873 10.02 EGFR KIT NKX2-1 PDGFRA PTEN PTPRC
14 no phenotypic analysis MP:0003012 10.01 CDKN2A CHGA EGFR KIT NKX2-1 PDGFRA
15 renal/urinary system MP:0005367 9.96 CHGA EGFR KIT KRT7 PDGFRA PTEN
16 reproductive system MP:0005389 9.81 CDKN2A CHGA EGFR KIT NKX2-1 PDGFRA
17 pigmentation MP:0001186 9.8 CDKN2A EGFR KIT PDGFRA PTEN TP53
18 respiratory system MP:0005388 9.65 CDKN2A EGFR ENO2 KIT NKX2-1 PDGFRA
19 skeleton MP:0005390 9.32 CDKN2A EGFR KIT NKX2-1 PDGFRA PTEN

Drugs & Therapeutics for Small Cell Carcinoma

Drugs for Small Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 470)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
2
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
3
Irinotecan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 100286-90-6, 97682-44-5 60838
4
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
5
Bupropion Approved Phase 4,Phase 3,Phase 2 34841-39-9, 34911-55-2 444
6
Dopamine Approved Phase 4,Phase 3,Phase 2 62-31-7, 51-61-6 681
7
Nicotine Approved Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 54-11-5 89594 942
8
Gefitinib Approved, Investigational Phase 4,Phase 2,Not Applicable 184475-35-2 123631
9 topoisomerase I inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
10 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
16 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2
17 Antidepressive Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
18 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
19 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Psychotropic Drugs Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
21 Dopamine Agents Phase 4,Phase 3,Phase 2
22 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 3,Phase 2
23 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2
24 Antidepressive Agents, Second-Generation Phase 4,Phase 3,Phase 2
25 Central Nervous System Stimulants Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1
26 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Nicotinic Agonists Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1
28 Cholinergic Agents Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1
29
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
30
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
31
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
32
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
33
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
34
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
35
Temozolomide Approved, Investigational Phase 2, Phase 3,Phase 1 85622-93-1 5394
36
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
37
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 119413-54-6, 123948-87-8 60700
38
Heparin Approved, Investigational Phase 3,Phase 2 9005-49-6 46507594 772
39
Dalteparin Approved Phase 3 9005-49-6
40
Mesna Approved, Investigational Phase 3 3375-50-6 598
41
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
42
Vinorelbine Approved, Investigational Phase 3,Phase 1,Phase 2 71486-22-1 44424639 60780
43
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
44
Enoxaparin Approved Phase 3,Phase 2 9005-49-6 772
45
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 216974-75-3
46
Ipilimumab Approved Phase 3,Phase 2,Phase 1 477202-00-9
47
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
48
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 143 6006
49
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 150399-23-8, 137281-23-3 60843 446556
50
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978

Interventional clinical trials:

(show top 50) (show all 874)
# Name Status NCT ID Phase Drugs
1 Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer Unknown status NCT02348450 Phase 4 Irinotecan;Etoposide;Cisplatin
2 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
3 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
4 Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride Not yet recruiting NCT03890055 Phase 4 Anlotinib Hydrochloride
5 the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer) Not yet recruiting NCT03264794 Phase 4 Gefitinib Tab (CTTQ),First medication;Gefitinib Tab (CTTQ),From the 8th day of trial;Gefitinib tablets (Yi Ruisha),First medication;Gefitinib Tab 250 MG(CTTQ),From the 8th day of trial.
6 Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy Suspended NCT01720901 Phase 4 Icotinib
7 STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study Unknown status NCT00526396 Phase 3 cisplatin;etoposide;cisplatin;etoposide
8 Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient Unknown status NCT00826644 Phase 3 Belotecan/Cisplatin;Etoposide/Cisplatin
9 Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer Unknown status NCT00003606 Phase 3 cisplatin;cyclophosphamide;epirubicin hydrochloride;etoposide
10 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Small Cell Lung Cancer Unknown status NCT00002858 Phase 3 cisplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide
11 Combination Chemotherapy in Treating Patients Who Have Extensive-Stage Small Cell Lung Cancer Unknown status NCT00003696 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;paclitaxel
12 Chemotherapy Followed by Peripheral Stem Cell or Bone Marrow Transplant Compared With Chemotherapy Alone in Treating Patients With Small Cell Lung Cancer Unknown status NCT00011921 Phase 3 carboplatin;epirubicin hydrochloride;etoposide;etoposide phosphate;ifosfamide;paclitaxel
13 Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer Unknown status NCT02772107 Phase 2, Phase 3 Temozolomide;first-line chemotherapy
14 Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study) Unknown status NCT01555710 Phase 3 Carboplatin;Palifosfamide-tris;Etoposide;Carboplatin
15 Study of Picoplatin Efficacy After Relapse Unknown status NCT00465491 Phase 3 picoplatin
16 A Study for Small Cell Lung Cancer (SCLC) in Extensive Disease Stage Unknown status NCT00168896 Phase 2, Phase 3 Carboplatin plus Irinotecan vs Carboplatin plus Etoposide
17 A Prospective Randomized Study Comparing the Target Volume for Limited-stage Small Cell Lung Cancer Unknown status NCT01731548 Phase 2, Phase 3
18 SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013 Unknown status NCT02738346 Phase 3 Carboplatin;Etoposide;Topotecan
19 Dalteparin in Preventing Blood Clots in Patients With Lung Cancer Unknown status NCT00519805 Phase 3 dalteparin
20 A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer Completed NCT00717938 Phase 3 cisplatinum or carboplatin and e.g.etoposide.;cisplatinum or carboplatin and e.g.etoposide+enoxaparin
21 Bevacizumab in Extensive Small Cell Lung Cancer Completed NCT00930891 Phase 2, Phase 3 Standard Chemotherapy (PCDE or PE);Experimental Treatment (PCDE or PE + bevacizumab);Prerandomization Chemotherapy (PCDE or PE)
22 AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy Completed NCT00547651 Phase 3 Amrubicin;Topotecan
23 Early Versus Late Concurrent Chemoradiation for Limited Stage Small-cell Lung Cancer Completed NCT01125995 Phase 3
24 Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone Completed NCT01450761 Phase 3 Etoposide;Cisplatin;Carboplatin
25 Marimastat Following Chemotherapy in Treating Patients With Small Cell Lung Cancer Completed NCT00003011 Phase 3 marimastat;Placebo
26 A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa Completed NCT00119613 Phase 3 placebo;darbepoetin alfa
27 Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults Completed NCT00043927 Phase 3 topotecan/cisplatin;etoposide/cisplatin
28 Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer Completed NCT00143455 Phase 3 Etoposide + cisplatin;Irinotecan + cisplatin
29 Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer Completed NCT00363415 Phase 3 pemetrexed;etoposide;carboplatin
30 Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer Completed NCT00658580 Phase 3 Cisplatin + etoposide;Epirubicin + ifosfamide + etoposide
31 Radiation Therapy Plus Combination Chemotherapy In Treating Patients With Limited Stage Small Cell Lung Cancer Completed NCT00003364 Phase 3 cisplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
32 Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer Completed NCT00003299 Phase 3 cisplatin;etoposide;paclitaxel
33 Radiation Therapy in Patients With Limited-Stage Small Cell Lung Cancer in Complete Remission Completed NCT00005062 Phase 3
34 Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer Completed NCT00006352 Phase 3
35 Carboplatin and Etoposide With or Without Thalidomide in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer Completed NCT00061919 Phase 3 Carboplatin, etoposide & thalidomide;Carboplatin, etoposide & placebo
36 Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer Completed NCT00006349 Phase 3 donepezil hydrochloride
37 S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer Completed NCT00045162 Phase 3 cisplatin;etoposide;irinotecan hydrochloride
38 Vaccination Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer Completed NCT00003279 Phase 3
39 Radiation Therapy to Prevent Brain Metastases in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer Completed NCT00016211 Phase 3
40 Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer Completed NCT00002822 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
41 Topotecan in Treating Patients With Relapsed Small Cell Lung Cancer Completed NCT00003917 Phase 3 topotecan hydrochloride
42 A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC Completed NCT00144989 Phase 3 Etoposide and cisplatin after chemoradiotherapy;Irinotecan and cisplatin after chemoradiotherapy
43 Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer Completed NCT00320359 Phase 3 Intravenous topotecan/cisplatin;Intravenous etoposide/cisplatin
44 Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG Completed NCT00037713 Phase 3
45 Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer Completed NCT00041015 Phase 3 cisplatin;etoposide;topotecan hydrochloride
46 A Study Comparing Etoposide/Cisplatin With Irinotecan/Cisplatin to Treat Extensive Disease Small Lung Cancer Completed NCT00349492 Phase 3 IP
47 Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell Lung Cancer Completed NCT00433498 Phase 3 carboplatin;cisplatin;etoposide phosphate;pravastatin sodium
48 Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer Completed NCT00660504 Phase 3 Amrubicin Hydrochloride;Etoposide-Cisplatin combined chemotherapy
49 Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide Completed NCT00290953 Phase 2, Phase 3 SR48692
50 Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer Completed NCT00276276 Phase 3 topotecan

Search NIH Clinical Center for Small Cell Carcinoma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Small Cell Carcinoma

Anatomical Context for Small Cell Carcinoma

MalaCards organs/tissues related to Small Cell Carcinoma:

42
Prostate, Lung, Brain, Ovary, Cervix, Bone, Liver

Publications for Small Cell Carcinoma

Articles related to Small Cell Carcinoma:

(show top 50) (show all 2495)
# Title Authors Year
1
Primary mixed adenocarcinoma and small-cell carcinoma of appendix: A case report (CARE-compliant). ( 31083256 )
2019
2
Transformation of epidermal growth factor receptor T790M mutation-positive adenosquamous carcinoma of the lung to small cell carcinoma and large-cell neuroendocrine carcinoma following osimertinib therapy: an autopsy case report. ( 30828454 )
2019
3
GABABR-Mediated Paraneoplastic Limbic Encephalitis Due To Thymic Small Cell Carcinoma. ( 31062226 )
2019
4
Paraneoplastic limbic encephalitis revealing a small cell carcinoma of the lung. ( 30622890 )
2019
5
Primary Gastric Small Cell Carcinoma: A Case Identified as a Large Subepithelial Tumor from Invisible State in 6 Months. ( 29976037 )
2019
6
Large Cell Neuroendocrine Carcinoma Shares Similarity with Small Cell Carcinoma on the Basis of Clinical and Pathological Features. ( 30818166 )
2019
7
Treatment-refractory paraneoplastic opsoclonus-myoclonus syndrome in a patient with small-cell carcinoma of the lung. ( 30791855 )
2019
8
Corrigendum: Treatment-refractory paraneoplastic opsoclonus-myoclonus syndrome in a patient with small cell carcinoma of the lung. ( 30907284 )
2019
9
Ovarian small cell carcinoma in one of a pair of monozygous twins. ( 30284660 )
2019
10
Ovarian Small Cell Carcinoma of Hypercalcemic Type in an Adolescent Girl. ( 30956495 )
2019
11
Molecular analysis and literature-based hypothesis of an immunonegative prostate small cell carcinoma causing ectopic ACTH syndrome. ( 30918166 )
2019
12
Correction to: Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung. ( 30306431 )
2019
13
Triple marker composed of p16, CD56, and TTF1 shows higher sensitivity than INSM1 for diagnosis of pulmonary small cell carcinoma: proposal for a rational immunohistochemical algorithm for diagnosis of small cell carcinoma in small biopsy and cytology specimens. ( 30385371 )
2019
14
Immunohistochemistry for small-cell carcinoma: a potential diagnostic pitfall. ( 30431185 )
2019
15
Cytopathologic characteristics of HPV-related small cell carcinoma of the oropharynx. ( 30468701 )
2019
16
Prognostic Role of S100A8 and S100A9 Protein Expressions in Non-small Cell Carcinoma of the Lung. ( 30472816 )
2019
17
An In-Depth Look at Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT): Clinical Implications from Recent Molecular Findings. ( 30662543 )
2019
18
CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary. ( 30718512 )
2019
19
Small cell carcinoma of cervix: A population-based study evaluating standardized provincial treatment protocols. ( 30723760 )
2019
20
Primary small cell carcinoma of the esophagus: Comparison between a Chinese cohort and Surveillance, Epidemiology, and End Results (SEER) data. ( 30740907 )
2019
21
First Case of Cellular Cannibalism in Small-Cell Carcinoma of the Bladder Detected in Peripheral Blood. ( 30809987 )
2019
22
Cytologic diagnosis of small cell carcinoma of the ovary: A case report with review of the literature. ( 30821422 )
2019
23
Small cell carcinoma of the kidney: a case report and analysis of data from the Surveillance, Epidemiology, and End Results registry. ( 30841901 )
2019
24
Primary small cell carcinoma of the vagina: a rare instance of prolonged survival. ( 30852510 )
2019
25
Survival outcomes after whole brain radiotherapy for brain metastases in older adults with newly diagnosed metastatic small cell carcinoma: A national cancer database (NCDB) analysis. ( 30876834 )
2019
26
The dilemma of early preventive oophorectomy in familial small cell carcinoma of the ovary of hypercalcemic type. ( 30886884 )
2019
27
Value of multimodality imaging in diagnosing primary small cell carcinoma of breast. ( 30925546 )
2019
28
Transcatheter Tumor Biopsy Combined With Balloon Pulmonary Angioplasty in Diagnosing Intravascular Pulmonary Small Cell Carcinoma. ( 30928448 )
2019
29
Azzopardi Phenomenon Associated with Small Cell Carcinoma. ( 30963714 )
2019
30
Small Cell Carcinoma: a Rare Subtype of Thyroid Cancer with Unanticipated Prognosis. ( 31016520 )
2019
31
Small Cell Carcinoma of the Esophagus: A Nationwide Analysis of Treatment and Outcome at Patient Level in Locoregional Disease. ( 31021827 )
2019
32
Organ-preserving approach via radiotherapy for small cell carcinoma of the bladder: an analysis based on the Japanese Radiation Oncology Study Group (JROSG) survey. ( 31034572 )
2019
33
Extrapulmonary Small Cell Carcinoma: An Unfortunate Case of Metastatic Disease. ( 29309906 )
2019
34
Evaluating Treatment Patterns for Small Cell Carcinoma of the Colon Using the National Cancer Database (NCDB). ( 29354876 )
2019
35
Unusual acute liver failure from small cell carcinoma of the lung. ( 30603677 )
2018
36
Synchronous Pulmonary Adenocarcinoma and Lymph Node Small Cell Carcinoma of Unknown Primary Origin. ( 30368412 )
2018
37
Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with lung adenocarcinoma harboring epidermal growth factor receptor mutations: A case report. ( 30310765 )
2018
38
A Case of Primary Pulmonary Combined Small Cell Carcinoma With Adenocarcinoma Harboring the Same KLC1-ALK Fusion in Both Histologic Components. ( 30244852 )
2018
39
Concomitant small cell carcinoma and adenocarcinoma of the gallbladder: a case report. ( 29923489 )
2018
40
Small-Cell Carcinoma Transformation of Pulmonary Adenocarcinoma after Osimertinib Treatment: A Case Report. ( 29928211 )
2018
41
Primary Gastric Small Cell Carcinoma (Presenting as Linitis Plastica) Diagnosed Using Endoscopic Ultrasound-Guided Biopsy: A Case Report. ( 30300982 )
2018
42
Insulinoma-associated protein 1 is a novel sensitive and specific marker for small cell carcinoma of the prostate. ( 29885405 )
2018
43
Insulinoma-Associated Protein 1 Immunostain: A Diagnostic Tool for Pulmonary Small Cell Carcinoma in Cytology. ( 29936498 )
2018
44
The use of adaptive intensity-modulated radiotherapy in the treatment of small-cell carcinoma lung refractory to chemotherapy in a patient with preexisting interstitial lung disease. ( 29319036 )
2018
45
Lambert-Eaton Myasthenic Syndrome Associated with Synchronous Double Cancer: A Combination of Small Cell Carcinoma of the Cervix and Breast Carcinoma. ( 29526952 )
2018
46
Ovarian Small Cell Carcinoma: A Rare Case Report and Review of Literature. ( 29731803 )
2018
47
Primary ovarian small cell carcinoma of pulmonary type with coexisting endometrial carcinoma in a breast cancer patient receiving tamoxifen: A case report and literature review. ( 29879027 )
2018
48
Whole-Exome Sequencing of Sinonasal Small Cell Carcinoma Arising within a Papillary Schneiderian Carcinoma In Situ. ( 29734873 )
2018
49
Pure Small Cell Carcinoma of Prostate: A Report of 8 Cases. ( 30269133 )
2018
50
Pediatric Patients with Small-Cell Carcinoma of the Ovary Have Similar Survival to Adults: A Review of the National Cancer Database. ( 30269708 )
2018

Variations for Small Cell Carcinoma

Expression for Small Cell Carcinoma

Search GEO for disease gene expression data for Small Cell Carcinoma.

Pathways for Small Cell Carcinoma

Pathways related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.66 CDKN2A EGFR KIT KLK3 PDGFRA PTEN
2
Show member pathways
12.57 EGFR KIT PDGFRA PTEN TP53
3
Show member pathways
12.55 CDKN2A EGFR PDGFRA PTEN TP53
4 12.53 CDKN2A EGFR KIT KLK3 PDGFRA PTEN
5 12.41 CALCA ENO2 NCAM1 NKX2-1 SYP
6
Show member pathways
12.38 EGFR PDGFRA PTEN TP53
7
Show member pathways
12.37 CDKN2A EGFR KIT PTEN SMARCA2 SMARCA4
8 12.31 CDKN2A EGFR PDGFRA PTEN TP53
9
Show member pathways
12.09 EGFR PDGFRA PTEN TP53
10 11.98 EGFR PDGFRA PTEN TP53
11 11.98 EGFR PTEN SMARCA4 TP53
12 11.88 EGFR PTEN SMARCA4 TP53
13 11.75 EGFR KLK3 PTEN
14
Show member pathways
11.69 SMARCA2 SMARCA4 TP53
15 11.67 KIT NCAM1 PTPRC
16 11.63 KIT NCAM1 PTPRC
17 11.62 CDKN2A EGFR TP53
18 11.6 NCAM1 PDGFRA SMARCA4 SYP
19
Show member pathways
11.59 EGFR SMARCA2 SMARCA4
20 11.54 PTEN SMARCA2 TP53
21 11.41 KIT NCAM1 PDGFRA
22 11.4 CDKN2A EGFR PDGFRA PTEN TP53
23 11.33 CDKN2A EGFR PDGFRA TP53
24 10.83 EGFR KIT PDGFRA PTEN TP53

GO Terms for Small Cell Carcinoma

Cellular components related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 npBAF complex GO:0071564 8.96 SMARCA2 SMARCA4
2 cytoplasmic side of plasma membrane GO:0009898 8.8 KIT PTEN PTPRC

Biological processes related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.85 CDKN2A EGFR NKX2-1 SMARCA2 SMARCA4 TP53
2 positive regulation of gene expression GO:0010628 9.83 CDKN2A KIT NKX2-1 PTEN TP53
3 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.77 EGFR KIT PDGFRA
4 MAPK cascade GO:0000165 9.76 EGFR KIT NCAM1 PDGFRA
5 lung development GO:0030324 9.75 EGFR NKX2-1 PDGFRA
6 negative regulation of apoptotic process GO:0043066 9.74 EGFR PTEN TP53
7 negative regulation of transcription, DNA-templated GO:0045892 9.73 CALCA CDKN2A NKX2-1 SMARCA2 SMARCA4 TP53
8 mast cell degranulation GO:0043303 9.58 CHGA KIT
9 positive regulation of phospholipase C activity GO:0010863 9.56 KIT PDGFRA
10 replicative senescence GO:0090399 9.55 CDKN2A TP53
11 tongue development GO:0043586 9.54 EGFR KIT
12 cerebral cortex cell migration GO:0021795 9.52 EGFR NKX2-1
13 Leydig cell differentiation GO:0033327 9.51 NKX2-1 PDGFRA
14 positive regulation of MAPK cascade GO:0043410 9.5 KIT PDGFRA PTPRC
15 somatic stem cell division GO:0048103 9.49 CDKN2A KIT
16 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.48 EGFR TP53
17 negative regulation of cell growth GO:0030308 9.46 CDKN2A SMARCA2 SMARCA4 TP53
18 mast cell chemotaxis GO:0002551 9.4 CHGA KIT
19 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.02 EGFR KIT PDGFRA PTEN PTPRC
20 mast cell cytokine production GO:0032762 8.96 CHGA KIT

Molecular functions related to Small Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.55 CDKN2A EGFR PTEN PTPRC TP53
2 nucleotide binding GO:0000166 9.35 EGFR KIT PDGFRA SMARCA2 SMARCA4
3 hydrolase activity, acting on acid anhydrides GO:0016817 9.26 SMARCA2 SMARCA4
4 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.8 EGFR KIT PDGFRA

Sources for Small Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....